PMC4784096_01
Bullous pemphigoid patient before and after omalizumab therapy. A, Abdominal involvement of steroid refractory BP patient prior to omalizumab therapy. B, Sixteen weeks after beginning omalizumab treatment the tense blisters and inflammatory plaques had resolved, leaving post-inflammatory hyperpigmentation and a small number of 4-6 mm erosions.
nihms103330f1.jpg
PMC4784096_01_nihms103330f1.jpg
F1
By week 16, her body surface involvement with urticarial plaques had declined from 50% to 5%, and the tense blisters characteristic of BP were resolved, although some small 4-6 mm erosions remained (see Figure 1).